CR11731A - Composiciones y procedimientos para su preparación y uso - Google Patents
Composiciones y procedimientos para su preparación y usoInfo
- Publication number
- CR11731A CR11731A CR11731A CR11731A CR11731A CR 11731 A CR11731 A CR 11731A CR 11731 A CR11731 A CR 11731A CR 11731 A CR11731 A CR 11731A CR 11731 A CR11731 A CR 11731A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- procedures
- preparation
- methods
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Composiciones, métodos para preparar las composiciones y métodos para tratar o prevenir enfermedades, que comprenden la administración de las composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4488608P | 2008-04-14 | 2008-04-14 | |
US15977809P | 2009-03-12 | 2009-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11731A true CR11731A (es) | 2011-06-08 |
Family
ID=41199689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11731A CR11731A (es) | 2008-04-14 | 2010-10-14 | Composiciones y procedimientos para su preparación y uso |
Country Status (20)
Country | Link |
---|---|
US (1) | US8808742B2 (es) |
EP (1) | EP2291350A4 (es) |
JP (1) | JP2011518786A (es) |
KR (1) | KR20110014149A (es) |
CN (1) | CN102131771A (es) |
AU (1) | AU2009236325A1 (es) |
BR (1) | BRPI0911297A2 (es) |
CA (1) | CA2720671A1 (es) |
CO (1) | CO6331425A2 (es) |
CR (1) | CR11731A (es) |
CU (1) | CU20100200A7 (es) |
DO (1) | DOP2010000304A (es) |
EA (1) | EA201001639A1 (es) |
EC (1) | ECSP10010548A (es) |
IL (1) | IL208284A0 (es) |
MA (1) | MA32226B1 (es) |
MX (1) | MX2010011314A (es) |
SG (1) | SG189784A1 (es) |
WO (1) | WO2009129246A2 (es) |
ZA (1) | ZA201006944B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
TWI524890B (zh) * | 2009-07-24 | 2016-03-11 | 亞德生化公司 | (r)-n-(3,4-二氟-2-(2-氟-4-碘苯胺基)-6-甲氧基苯基)-1-(2,3-二羥丙基)環丙烷-1-磺醯胺及(s)-n-(3,4-二氟-2-(2-氟-4-碘苯胺基)-6-甲氧基苯基)-1-(2,3-二羥丙基)環丙烷-1-磺醯胺之製備 |
KR20120094165A (ko) | 2009-10-13 | 2012-08-23 | 알로스팀 테라퓨틱스 엘엘씨 | 질병의 치료에 유용한 신규 mek 억제제 |
EA201201414A8 (ru) * | 2010-04-16 | 2013-12-30 | Байер Интеллектчуал Проперти Гмбх | КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
NZ702548A (en) | 2012-06-04 | 2015-11-27 | Pharmacyclics Llc | Crystalline forms of a bruton’s tyrosine kinase inhibitor |
CN103570594A (zh) * | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
WO2014071183A1 (en) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
EP2848246A1 (en) * | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
EP3043778B1 (en) * | 2013-09-13 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
AU2016317574A1 (en) | 2015-08-28 | 2018-03-29 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
EP3341739A4 (en) | 2015-08-28 | 2019-07-10 | BioIncept LLC | MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH |
EP3609464B1 (en) * | 2017-04-13 | 2021-05-26 | Jean Paul Remon | Xanthohumol-based compositions |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN113476476A (zh) * | 2021-08-25 | 2021-10-08 | 娜布其 | 一种治疗白癜风疾病的药物及其制作工艺 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8005A (en) * | 1851-04-01 | He ne y bo o t | ||
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
CZ20012528A3 (cs) * | 1999-01-13 | 2002-06-12 | Warner-Lambert Company | 1-Heterocyklicky substituované diarylaminy, farmaceutické kompozice na jejich bázi a způsoby léčení |
US8648116B2 (en) * | 2005-07-21 | 2014-02-11 | Ardea Biosciences, Inc. | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same |
US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
AU2006272837B2 (en) | 2005-07-21 | 2012-08-23 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of MEK |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
CA2693390C (en) * | 2007-07-30 | 2017-01-17 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
US8044240B2 (en) * | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
-
2009
- 2009-04-14 EP EP09732683A patent/EP2291350A4/en not_active Withdrawn
- 2009-04-14 AU AU2009236325A patent/AU2009236325A1/en not_active Abandoned
- 2009-04-14 SG SG2013028378A patent/SG189784A1/en unknown
- 2009-04-14 US US12/937,630 patent/US8808742B2/en not_active Expired - Fee Related
- 2009-04-14 WO PCT/US2009/040538 patent/WO2009129246A2/en active Application Filing
- 2009-04-14 BR BRPI0911297A patent/BRPI0911297A2/pt not_active IP Right Cessation
- 2009-04-14 CN CN2009801180672A patent/CN102131771A/zh active Pending
- 2009-04-14 KR KR1020107025394A patent/KR20110014149A/ko not_active Application Discontinuation
- 2009-04-14 EA EA201001639A patent/EA201001639A1/ru unknown
- 2009-04-14 JP JP2011505138A patent/JP2011518786A/ja active Pending
- 2009-04-14 MX MX2010011314A patent/MX2010011314A/es active IP Right Grant
- 2009-04-14 CA CA2720671A patent/CA2720671A1/en not_active Abandoned
-
2010
- 2010-09-21 IL IL208284A patent/IL208284A0/en unknown
- 2010-09-29 ZA ZA2010/06944A patent/ZA201006944B/en unknown
- 2010-10-13 CU CU2010000200A patent/CU20100200A7/es active IP Right Grant
- 2010-10-14 CR CR11731A patent/CR11731A/es not_active Application Discontinuation
- 2010-10-14 EC EC2010010548A patent/ECSP10010548A/es unknown
- 2010-10-14 MA MA33245A patent/MA32226B1/fr unknown
- 2010-10-14 CO CO10128068A patent/CO6331425A2/es not_active Application Discontinuation
- 2010-10-14 DO DO2010000304A patent/DOP2010000304A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009129246A2 (en) | 2009-10-22 |
US20110033539A1 (en) | 2011-02-10 |
CU23904B1 (es) | 2013-06-28 |
CO6331425A2 (es) | 2011-10-20 |
MX2010011314A (es) | 2010-11-12 |
CU20100200A7 (es) | 2011-11-15 |
CA2720671A1 (en) | 2009-10-22 |
ECSP10010548A (es) | 2010-11-30 |
BRPI0911297A2 (pt) | 2019-09-24 |
KR20110014149A (ko) | 2011-02-10 |
SG189784A1 (en) | 2013-05-31 |
JP2011518786A (ja) | 2011-06-30 |
AU2009236325A1 (en) | 2009-10-22 |
IL208284A0 (en) | 2010-12-30 |
ZA201006944B (en) | 2015-06-24 |
EA201001639A1 (ru) | 2011-06-30 |
EP2291350A4 (en) | 2012-09-19 |
WO2009129246A3 (en) | 2011-03-31 |
MA32226B1 (fr) | 2011-04-01 |
US8808742B2 (en) | 2014-08-19 |
CN102131771A (zh) | 2011-07-20 |
DOP2010000304A (es) | 2011-10-15 |
EP2291350A2 (en) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
BRPI0916235A2 (pt) | composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CR8778A (es) | Revestimientos de azucar y metodos para estos | |
CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
CL2007002635A1 (es) | Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion. | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
SV2010003559A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |